Putting a HER2 drug into the spinal fluid for breast cancer that spread to the brain
Original title: Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is an early test in people, and safety is the first thing being checked.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study tests giving a HER2 breast cancer drug right into the fluid around the brain.
Who this trial is for. This trial is for people with HER2 breast cancer that has spread to the brain or its lining. It tests a drug called T-DXd put into the spinal fluid, along with usual whole-body treatment.
Where it stands. The trial has not reported results. It is looking at safety and at how well the drug works inside the brain. It also measures how much drug reaches the spinal fluid and the blood. Those answers are not in yet.
What this means, and what it doesn't
What it could mean: Drugs given by vein often do not reach the brain well. This study asks if sending the drug straight into the spinal fluid helps. Someone who fits this picture could ask their care team about it.
What it doesn't mean: This does not mean the drug works when given this way. A trial is a test, not a proven treatment. Being in one is not a guarantee of any benefit. It is not a promise of a cure.
Source: ClinicalTrials.gov, October 26, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.